Meeder Advisory Services Inc. Buys 541 Shares of Eli Lilly and Company (NYSE:LLY)

Meeder Advisory Services Inc. increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,302 shares of the company's stock after acquiring an additional 541 shares during the quarter. Eli Lilly and Company comprises approximately 0.8% of Meeder Advisory Services Inc.'s portfolio, making the stock its 24th biggest position. Meeder Advisory Services Inc.'s holdings in Eli Lilly and Company were worth $12,585,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Groupama Asset Managment boosted its position in Eli Lilly and Company by 3.8% during the 4th quarter. Groupama Asset Managment now owns 91,838 shares of the company's stock valued at $71,068,000 after acquiring an additional 3,373 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Eli Lilly and Company by 73.4% during the fourth quarter. Trexquant Investment LP now owns 4,421 shares of the company's stock valued at $3,413,000 after purchasing an additional 1,871 shares in the last quarter. May Hill Capital LLC bought a new position in Eli Lilly and Company in the fourth quarter worth $1,205,000. Invenio Wealth Partners LLC lifted its position in Eli Lilly and Company by 6.5% during the fourth quarter. Invenio Wealth Partners LLC now owns 1,609 shares of the company's stock valued at $1,242,000 after buying an additional 98 shares during the period. Finally, PFC Capital Group Inc. boosted its holdings in shares of Eli Lilly and Company by 0.6% during the 4th quarter. PFC Capital Group Inc. now owns 6,290 shares of the company's stock valued at $4,855,000 after buying an additional 40 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent research reports. Citigroup lowered their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Truist Financial boosted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Morgan Stanley set a $1,146.00 target price on Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $1,009.72.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $14.34 on Wednesday, reaching $819.57. The company's stock had a trading volume of 2,678,114 shares, compared to its average volume of 3,311,810. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The stock's 50 day simple moving average is $848.85 and its two-hundred day simple moving average is $834.05. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $777.09 billion, a P/E ratio of 69.99, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has initiated a stock repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.